logo
Plus   Neg
Share
Email

MorphoSys : FDA Accepts BLA On Relapsed/refractory Diffuse Large B Cell Lymphoma

MorphoSys AG (MOR) said that the U.S. Food and Drug Administration accepted filing of the company's Biologics License Application or BLA and granted priority review for the company investigational anti-CD19 antibody, tafasitamab, under review in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B cell lymphoma.

The priority review designation shortens the FDA review period following the acceptance of the BLA to six months compared to ten months under Standard Review.

The FDA has set a Prescription Drug User Fee Act goal date of August 30, 2020. The FDA has informed MorphoSys that they are not currently planning to hold an advisory committee meeting to discuss the application.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Beginning July 6, Google plans to reopen offices in more cities, which were closed following the coronavirus pandemic-related lockdowns across the globe, Chief Executive Officer Sundar Pichai told employees in an email. However, the search giant still expects and encourages most Googlers to largely work from home for the rest of 2020. For those working from home, the company offered an allowance. Bristol Myers Squibb (BMY) announced Wednesday that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. With the EC marketing authorization,... Off-price retailer Tuesday Morning Corp. (TUES) on Wednesday filed voluntary petitions for protection under Chapter 11 of the Bankruptcy Code in the U. S. Bankruptcy Court for the Northern District of Texas, Dallas Division. It plans to emerge as a stronger company by early fall 2020. The company...
Follow RTT